Prognostic factors in stage III non-small-cell lung cancer

Foluso O. Ademuyiwa, Cynthia S. Johnson, Angela S. White, Timothy E. Breen, Jayme Harvey, Marcus Neubauer, Nasser Hanna

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

PURPOSE: The aim of this study is to present an analysis investigating the association of patient characteristics with overall survival (OS) in individuals with stage III non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Ten prognostic factors were analyzed in 203 patients with NSCLC who were enrolled in a phase III trial conducted by the Hoosier Oncology Group and US Oncology between 2002 and 2006. Eligible patients had untreated stage III NSCLC, forced expiratory volume in one second (FEV1) ≥ 1 liter, baseline performance status of 0/1, and weight loss < 5% in 3 months preceding the trial. Univariate analysis, Cox proportional hazards regression, and parametric accelerated failure time models were performed to identify the factors that affected survival duration. Variables analyzed included age (< 70 years vs. ≥ 70 years), sex, ethnicity, body mass index, performance status (0 vs. 1), FEV1 (> 2 L vs. 1-2 L), smoking status (current vs. never/former), hemoglobin (Hb) level, use of positron emission tomography scan in staging, and stage (IIIA vs. IIIB). RESULTS: Median follow-up was 25.6 months and the median OS was 21.2 months. The univariate analysis showed that Hb levels ≥ 12 were associated with an improved survival (P = .033). The multivariable parametric accelerated failure time model demonstrated the association of FEV1 > 2 L (P = .014), and higher pretreatment Hb values (P = .007) as independent prognostic factors for OS. Similarly in the Cox regression, survival was influenced by Hb and FEV1 > 2 L. CONCLUSION: This analysis suggests that FEV1 > 2 L and higher pretreatment Hb values are associated with improved OS in patients with stage III NSCLC. These factors can be useful in predicting for more favorable outcomes in patients with stage III NSCLC and provide additional information when designing future studies.

Original languageEnglish
Pages (from-to)478-482
Number of pages5
JournalClinical Lung Cancer
Volume8
Issue number8
DOIs
StatePublished - Sep 2007

Fingerprint

Non-Small Cell Lung Carcinoma
Survival
Hemoglobins
Forced Expiratory Volume
Positron-Emission Tomography
Weight Loss
Smoking

Keywords

  • FEV
  • Overall survival
  • Radiation therapy

ASJC Scopus subject areas

  • Cancer Research
  • Pulmonary and Respiratory Medicine

Cite this

Ademuyiwa, F. O., Johnson, C. S., White, A. S., Breen, T. E., Harvey, J., Neubauer, M., & Hanna, N. (2007). Prognostic factors in stage III non-small-cell lung cancer. Clinical Lung Cancer, 8(8), 478-482. https://doi.org/10.3816/CLC.2007.n.031

Prognostic factors in stage III non-small-cell lung cancer. / Ademuyiwa, Foluso O.; Johnson, Cynthia S.; White, Angela S.; Breen, Timothy E.; Harvey, Jayme; Neubauer, Marcus; Hanna, Nasser.

In: Clinical Lung Cancer, Vol. 8, No. 8, 09.2007, p. 478-482.

Research output: Contribution to journalArticle

Ademuyiwa, FO, Johnson, CS, White, AS, Breen, TE, Harvey, J, Neubauer, M & Hanna, N 2007, 'Prognostic factors in stage III non-small-cell lung cancer', Clinical Lung Cancer, vol. 8, no. 8, pp. 478-482. https://doi.org/10.3816/CLC.2007.n.031
Ademuyiwa FO, Johnson CS, White AS, Breen TE, Harvey J, Neubauer M et al. Prognostic factors in stage III non-small-cell lung cancer. Clinical Lung Cancer. 2007 Sep;8(8):478-482. https://doi.org/10.3816/CLC.2007.n.031
Ademuyiwa, Foluso O. ; Johnson, Cynthia S. ; White, Angela S. ; Breen, Timothy E. ; Harvey, Jayme ; Neubauer, Marcus ; Hanna, Nasser. / Prognostic factors in stage III non-small-cell lung cancer. In: Clinical Lung Cancer. 2007 ; Vol. 8, No. 8. pp. 478-482.
@article{8c32e9ffcbcc439fb3fd2fd27db36d4f,
title = "Prognostic factors in stage III non-small-cell lung cancer",
abstract = "PURPOSE: The aim of this study is to present an analysis investigating the association of patient characteristics with overall survival (OS) in individuals with stage III non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Ten prognostic factors were analyzed in 203 patients with NSCLC who were enrolled in a phase III trial conducted by the Hoosier Oncology Group and US Oncology between 2002 and 2006. Eligible patients had untreated stage III NSCLC, forced expiratory volume in one second (FEV1) ≥ 1 liter, baseline performance status of 0/1, and weight loss < 5{\%} in 3 months preceding the trial. Univariate analysis, Cox proportional hazards regression, and parametric accelerated failure time models were performed to identify the factors that affected survival duration. Variables analyzed included age (< 70 years vs. ≥ 70 years), sex, ethnicity, body mass index, performance status (0 vs. 1), FEV1 (> 2 L vs. 1-2 L), smoking status (current vs. never/former), hemoglobin (Hb) level, use of positron emission tomography scan in staging, and stage (IIIA vs. IIIB). RESULTS: Median follow-up was 25.6 months and the median OS was 21.2 months. The univariate analysis showed that Hb levels ≥ 12 were associated with an improved survival (P = .033). The multivariable parametric accelerated failure time model demonstrated the association of FEV1 > 2 L (P = .014), and higher pretreatment Hb values (P = .007) as independent prognostic factors for OS. Similarly in the Cox regression, survival was influenced by Hb and FEV1 > 2 L. CONCLUSION: This analysis suggests that FEV1 > 2 L and higher pretreatment Hb values are associated with improved OS in patients with stage III NSCLC. These factors can be useful in predicting for more favorable outcomes in patients with stage III NSCLC and provide additional information when designing future studies.",
keywords = "FEV, Overall survival, Radiation therapy",
author = "Ademuyiwa, {Foluso O.} and Johnson, {Cynthia S.} and White, {Angela S.} and Breen, {Timothy E.} and Jayme Harvey and Marcus Neubauer and Nasser Hanna",
year = "2007",
month = "9",
doi = "10.3816/CLC.2007.n.031",
language = "English",
volume = "8",
pages = "478--482",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "8",

}

TY - JOUR

T1 - Prognostic factors in stage III non-small-cell lung cancer

AU - Ademuyiwa, Foluso O.

AU - Johnson, Cynthia S.

AU - White, Angela S.

AU - Breen, Timothy E.

AU - Harvey, Jayme

AU - Neubauer, Marcus

AU - Hanna, Nasser

PY - 2007/9

Y1 - 2007/9

N2 - PURPOSE: The aim of this study is to present an analysis investigating the association of patient characteristics with overall survival (OS) in individuals with stage III non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Ten prognostic factors were analyzed in 203 patients with NSCLC who were enrolled in a phase III trial conducted by the Hoosier Oncology Group and US Oncology between 2002 and 2006. Eligible patients had untreated stage III NSCLC, forced expiratory volume in one second (FEV1) ≥ 1 liter, baseline performance status of 0/1, and weight loss < 5% in 3 months preceding the trial. Univariate analysis, Cox proportional hazards regression, and parametric accelerated failure time models were performed to identify the factors that affected survival duration. Variables analyzed included age (< 70 years vs. ≥ 70 years), sex, ethnicity, body mass index, performance status (0 vs. 1), FEV1 (> 2 L vs. 1-2 L), smoking status (current vs. never/former), hemoglobin (Hb) level, use of positron emission tomography scan in staging, and stage (IIIA vs. IIIB). RESULTS: Median follow-up was 25.6 months and the median OS was 21.2 months. The univariate analysis showed that Hb levels ≥ 12 were associated with an improved survival (P = .033). The multivariable parametric accelerated failure time model demonstrated the association of FEV1 > 2 L (P = .014), and higher pretreatment Hb values (P = .007) as independent prognostic factors for OS. Similarly in the Cox regression, survival was influenced by Hb and FEV1 > 2 L. CONCLUSION: This analysis suggests that FEV1 > 2 L and higher pretreatment Hb values are associated with improved OS in patients with stage III NSCLC. These factors can be useful in predicting for more favorable outcomes in patients with stage III NSCLC and provide additional information when designing future studies.

AB - PURPOSE: The aim of this study is to present an analysis investigating the association of patient characteristics with overall survival (OS) in individuals with stage III non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Ten prognostic factors were analyzed in 203 patients with NSCLC who were enrolled in a phase III trial conducted by the Hoosier Oncology Group and US Oncology between 2002 and 2006. Eligible patients had untreated stage III NSCLC, forced expiratory volume in one second (FEV1) ≥ 1 liter, baseline performance status of 0/1, and weight loss < 5% in 3 months preceding the trial. Univariate analysis, Cox proportional hazards regression, and parametric accelerated failure time models were performed to identify the factors that affected survival duration. Variables analyzed included age (< 70 years vs. ≥ 70 years), sex, ethnicity, body mass index, performance status (0 vs. 1), FEV1 (> 2 L vs. 1-2 L), smoking status (current vs. never/former), hemoglobin (Hb) level, use of positron emission tomography scan in staging, and stage (IIIA vs. IIIB). RESULTS: Median follow-up was 25.6 months and the median OS was 21.2 months. The univariate analysis showed that Hb levels ≥ 12 were associated with an improved survival (P = .033). The multivariable parametric accelerated failure time model demonstrated the association of FEV1 > 2 L (P = .014), and higher pretreatment Hb values (P = .007) as independent prognostic factors for OS. Similarly in the Cox regression, survival was influenced by Hb and FEV1 > 2 L. CONCLUSION: This analysis suggests that FEV1 > 2 L and higher pretreatment Hb values are associated with improved OS in patients with stage III NSCLC. These factors can be useful in predicting for more favorable outcomes in patients with stage III NSCLC and provide additional information when designing future studies.

KW - FEV

KW - Overall survival

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=35349018648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35349018648&partnerID=8YFLogxK

U2 - 10.3816/CLC.2007.n.031

DO - 10.3816/CLC.2007.n.031

M3 - Article

VL - 8

SP - 478

EP - 482

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 8

ER -